Physician profile
Diego Rielo
NPI 1720058233
$6,311.83
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $6,312.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $6,016.02 | 2019 | |
| Avanir Pharmaceuticals, INC. | $70.81 | 2019 | |
| Livanova USA, INC. | $46.59 | 2019 | |
| Adamas Pharmaceuticals, INC. | $43.19 | 2019 | |
| Acadia Pharmaceuticals INC | $41.89 | 2019 | |
| Ucb, INC. | $30.20 | 2019 | |
| Amgen INC. | $28.25 | 2019 | |
| Genentech USA, INC. | $18.50 | 2019 | |
| Amneal Pharmaceuticals LLC | $16.38 | 2019 |
6 companies reported research payments only; those appear in the research section below.
Research and ownership
$1,697.26 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diego Rielo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.